Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström's Macroglobulinemia. Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Ibrutinib was approved for use in chronic graft versus host disease in August 2017.

Ibrutinib is used to treat certain types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in people with or without 17p deletion.

Take ibrutinib exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.

The recommended dose of ibrutinib for mantle cell lymphoma (MCL) and Marginal zone lymphoma (MZL) is 560 mg (four 140 mg capsules) by mouth once daily.

The recommended dose of ibrutinib for chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma and Waldenström’s macroglobulinemia (WM), and chronic graft versus host disease is 420 mg taken orally once daily (three 140 mg capsules once daily).